Investor buys BioMatrix
By HME News Staff
Updated 8:56 AM CDT, Tue June 25, 2024
SEATTLE – Frazier Healthcare Partners, a Seattle-based, health care-focused investment firm, has closed on its acquisition of BioMatrix Holdings, a Plantation, Fla.-based national provider of home infusion services.
Frazier is partnering with Ted and Kathee Kramm, two highly experienced industry executives in the home infusion market, to lead BioMatrix with Ted as CEO and Kathee as president. The Kramms began their careers as clinicians (pharmacist and nurse, respectively) and have scaled multiple infusion pharmacy businesses, including AxelaCare, which, over the course of a decade, grew into one of the largest providers of home infusion services in the country.
“Backing best-in-class operators is a core tenet of our investment strategy, and we are thrilled to back Ted and Kathee,” said Frazier Partner Philip Zaorski. “As they have done previously, our shared vision for this asset is to build a nationally renowned platform that puts the patient at the center of everything we do.”
BioMatrix serves a diversified base of patients with more than 2,500 physician-referral relationships across all 50 states. It specializes in neurological diseases, immunology deficiencies and transplants, as well as blood disorders.
Comments